bekhterevОбозрение психиатрии и медицинской психологии имени В.М.БехтереваV.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY2313-70532713-055XV. M. BEKHTEREV NATIONAL RESEARCH MEDICAL CENTER FOR PSYCHIATRY AND NEUROLOGY OF THE RUSSIAN FEDERATION MINISTRY OF HEALTH10.31363/2313-7053-2022-4-101-106bekhterev-755Research ArticleВ ПОМОЩЬ ПРАКТИКУЮЩЕМУ ВРАЧУGUIDELINES FOR THE PRACTITIONERКлинический случай применения карипразина при терапевтически резистентной простой шизофренииClinical case of the use of cariprazine in treatment-resistant simple schizophreniahttps://orcid.org/0000-0003-1874-9434НасыроваР. Ф.NasyrovaR. F.

Регина Фаритовна Насырова, д. м. н., гл. н. с., консультант

Санкт-Петербург

188357

ул. Меньковская, д. 10

Ленинградская обл.

Гатчинский р-н

с. Никольское

Regina F. Nasyrova

St. Petersburg

reginaf@bekhterev.ruНациональный медицинский исследовательский центр психиатрии и неврологии им. В. М. Бехтерева; Санкт-Петербургская городская психиатрическая больница № 1 им. П. П. КащенкоРоссияV. M. Bekhterev National Research Center for Psychiatry and Neurology; P. P. Kashchenko Saint Petersburg Psychiatric Hospital № 1Russian Federation202218122022564101106Copyright © Насырова Р.Ф., 20222022Насырова Р.Ф.Nasyrova R.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.bekhterevreview.com/jour/article/view/755

   Рассмотрен клинический случай применения карипразина у пациентки с терапевтически резистентной простой шизофренией. Представлены дебют и развитие расстройства, фармакологический анамнез. Проанализированы клинические и фармакологические аспекты обоснования выбора карипразина в качестве эффективного и безопасного препарата для лечения шизофрении с преобладающими негативными симптомами.

   A clinical case of the use of cariprazine in a patient with therapeutically resistant simple schizophrenia is considered. The debut and development of the disorder, pharmacological history are presented. The clinical and pharmacological aspects of the rationale for choosing cariprazine as an effective and safe drug for the treatment of schizophrenia with predominantly negative symptoms are analyzed.

 

карипразиншизофренияпсихофармакотерапиятерапевтическая резистентностьнежелательные реакцииcariprazineschizophreniapsychopharmacotherapytherapeutically resistantadverse effectsReferencesCalabrese F., Tarazi F. I., Racagni G., Riva M A. The role of dopamine D3 receptors in the mechanism of action of cariprazine. CNS Spectr. 2020; 25 (3): 343–351. doi: 10.1017/S109285291900083X.Calabrese F., Tarazi F. I., Racagni G., Riva M A. The role of dopamine D3 receptors in the mechanism of action of cariprazine. CNS Spectr. 2020; 25 (3): 343–351. doi: 10.1017/S109285291900083X.Cerveri G., Gesi C., Mencacci C. Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm. Neuropsychiatr Dis Treat. 2019; 15: 1525–1535. doi: 10.2147/NDT.S201726Cerveri G., Gesi C., Mencacci C. Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm. Neuropsychiatr Dis Treat. 2019; 15: 1525–1535. doi: 10.2147/NDT.S201726Fagiolini A., Alcalá J., Aubel T., et al. Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an international panel. Ann Gen Psychiatry. 2020; 19: 55. doi: 10.1186/s12991-020-00305-3.Fagiolini A., Alcalá J., Aubel T., et al. Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an international panel. Ann Gen Psychiatry. 2020; 19: 55. doi: 10.1186/s12991-020-00305-3.Garcia S., Martinez-Cengotitabengoa M., Lopez-Zurbano S., et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. J Clin Psychopharmacol. 2016; 36 (4): 355–371. doi: 10.1097/JCP.0000000000000523Garcia S., Martinez-Cengotitabengoa M., Lopez-Zurbano S., et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. J Clin Psychopharmacol. 2016; 36 (4): 355–371. doi: 10.1097/JCP.0000000000000523Girgis R. R., Slifstein M., D’Souza D., et al. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11) C]-(+)-PHNO. Psychopharmacology. 2016; 233 (19–20): 3503–3512. doi: 10.1007/s00213-016-4382-y.Girgis R. R., Slifstein M., D’Souza D., et al. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11) C]-(+)-PHNO. Psychopharmacology. 2016; 233 (19–20): 3503–3512. doi: 10.1007/s00213-016-4382-y.Haddad P. M., Correll C. U. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Ther Adv Psychopharmacol. 2018; 8 (11): 303–318. doi: 10.1177/2045125318781475.Haddad P. M., Correll C. U. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Ther Adv Psychopharmacol. 2018; 8 (11): 303–318. doi: 10.1177/2045125318781475.Howes O. D., Thase M. E., Pillinger T. Treatment resistance in psychiatry: State of the art and new directions. Mol. Psychiatry.2022; 27: 58–72.Howes O. D., Thase M. E., Pillinger T. Treatment resistance in psychiatry: State of the art and new directions. Mol. Psychiatry.2022; 27: 58–72.Huhn M., Nikolakopoulou A., Schneider-Thoma J., et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019; 394 (10202): 939–951. doi: 10.1016/S0140-6736(19)31135-3Huhn M., Nikolakopoulou A., Schneider-Thoma J., et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019; 394 (10202): 939–951. doi: 10.1016/S0140-6736(19)31135-3Hunter R., Barry S. Negative symptoms and psychosocial functioning in schizophrenia: neglected but important targets for treatment. Eur Psychiatry. 2012; 27 (6): 432–436. doi: 10.1016/j.eurpsy.2011.02.015.Hunter R., Barry S. Negative symptoms and psychosocial functioning in schizophrenia: neglected but important targets for treatment. Eur Psychiatry. 2012; 27 (6): 432–436. doi: 10.1016/j.eurpsy.2011.02.015.Insel TR. Rethinking schizophrenia. Nature. 2010; 468 (7321): 187–193. doi: 10.1038/nature09552.Insel TR. Rethinking schizophrenia. Nature. 2010; 468 (7321): 187–193. doi: 10.1038/nature09552.Kanchanatawan B., Thika S., Anderson G., Galecki P., Maes M. Affective symptoms in schizophrenia are strongly associated with neurocognitive deficits indicating disorders in executive functions, visual memory, attention and social cognition. Prog Neuropsychopharmacol Biol Psychiatry. 2018; 80 (Pt C): 168–176. doi: 10.1016/j.pnpbp.2017.06.031.Kanchanatawan B., Thika S., Anderson G., Galecki P., Maes M. Affective symptoms in schizophrenia are strongly associated with neurocognitive deficits indicating disorders in executive functions, visual memory, attention and social cognition. Prog Neuropsychopharmacol Biol Psychiatry. 2018; 80 (Pt C): 168–176. doi: 10.1016/j.pnpbp.2017.06.031.Kane J. M., Agid O., Baldwin M. L., Howes O., Lindenmayer J. P., Marder S., Olfson M., Potkin S. G., Correll C. U. Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia. J. Clin. Psychiatry. 2019; 80: 2783.Kane J. M., Agid O., Baldwin M. L., Howes O., Lindenmayer J. P., Marder S., Olfson M., Potkin S. G., Correll C. U. Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia. J. Clin. Psychiatry. 2019; 80: 2783.Keks N., Hope J., Schwartz D., et al. Comparative tolerability of dopamine D2/3 receptor partial agonists for schizophrenia. CNS Drugs. 2020; 34 (5): 473–507. doi: 10.1007/s40263-020-00718-4.Keks N., Hope J., Schwartz D., et al. Comparative tolerability of dopamine D2/3 receptor partial agonists for schizophrenia. CNS Drugs. 2020; 34 (5): 473–507. doi: 10.1007/s40263-020-00718-4.Laursen T. M. Life expectancy among personswith schizophrenia or bipolar affective disorder. Schizophr. 2011; 131: 101–104.Laursen T. M. Life expectancy among personswith schizophrenia or bipolar affective disorder. Schizophr. 2011; 131: 101–104.Laszlovszky I., Barabássy Á., Németh G. Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety Adv Ther. 2021; 38 (7): 3652–3673. doi: 10.1007/s12325-021-01797-5.Laszlovszky I., Barabássy Á., Németh G. Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety Adv Ther. 2021; 38 (7): 3652–3673. doi: 10.1007/s12325-021-01797-5.Owen M. J., Sawa A., Mortensen P. B. Schizophrenia. Lancet. 2016; 388 (10039): 86–97. doi: 10.1016/S0140-6736(15)01121-6.Owen M. J., Sawa A., Mortensen P. B. Schizophrenia. Lancet. 2016; 388 (10039): 86–97. doi: 10.1016/S0140-6736(15)01121-6.Perälä J., Suvisaari J., Saarni S. I., et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007; 64 (1): 19–28. doi: 10.1001/archpsyc.64.1.19.Perälä J., Suvisaari J., Saarni S. I., et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007; 64 (1): 19–28. doi: 10.1001/archpsyc.64.1.19.Pillinger T., McCutcheon R. A., Vano L., et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020; 7 (1): 64–77. doi: 10.1016/S2215-0366(19)30416-X.Pillinger T., McCutcheon R. A., Vano L., et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020; 7 (1): 64–77. doi: 10.1016/S2215-0366(19)30416-X.Rabinowitz J., Berardo C. G., Bugarski-Kirola D., Marder S. Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysis. Schizophr. 2013; 150 (2–3): 339–342. doi: 10.1016/j.schres.2013.07.014.Rabinowitz J., Berardo C. G., Bugarski-Kirola D., Marder S. Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysis. Schizophr. 2013; 150 (2–3): 339–342. doi: 10.1016/j.schres.2013.07.014.Saha S., Chant D., McGrath J. A systematic review of mortality in schizophrenia: Is the differential mortality gap worsening over time? Arch. Gen. Psychiatry. 2007; 64: 1123–1131.Saha S., Chant D., McGrath J. A systematic review of mortality in schizophrenia: Is the differential mortality gap worsening over time? Arch. Gen. Psychiatry. 2007; 64: 1123–1131.Suttajit S., Pilakanta S. Predictors of quality of life among individuals with schizophrenia. Neuropsychiatr Dis Treat. 2015; 11: 1371–1379. doi: 10.2147/NDT.S81024.Suttajit S., Pilakanta S. Predictors of quality of life among individuals with schizophrenia. Neuropsychiatr Dis Treat. 2015; 11: 1371–1379. doi: 10.2147/NDT.S81024.Vita A., Barlati S. Recovery from schizophrenia: is it possible? Curr Opin Psychiatry. 2018; 31 (3): 246–255. doi: 10.1097/YCO.0000000000000407Vita A., Barlati S. Recovery from schizophrenia: is it possible? Curr Opin Psychiatry. 2018; 31 (3): 246–255. doi: 10.1097/YCO.0000000000000407

The authors declare that there are no conflicts of interest present.